According to the results of a phase III trial, the addition of stereotactic body radiation therapy to sorafenib for the treatment of patients with hepatocellular carcinoma not only prolongs survival but also seems to improve quality of life compared with sorafenib alone.

©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.